AbbVie to Buy Cerevel Therapeutics for $8.7 Billion

AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics Holdings for $45 a share, giving the company an equity value of about $8.7 billion.

The deal is AbbVie’s second major acquisition announced in the last two weeks, after the pharmaceutical giant announced Nov. 30 it would acquire ImmunoGen for $10 billion.